Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026)
Perspective Therapeutics' (CATX) quarterly Change in Receivables came in at $211000.0 in Q2 2026, up 43.54% year-over-year from $147000.0 in Q2 2025, and up 305.77% quarter-over-quarter from $52000.0 in Q1 2026.
Powered by 
Analysis
Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Change in Receivables across 17 years of filings, most recently posting $211000.0 for Q2 2026.
- In Q2 2026, Change in Receivables rose 43.54% year-over-year to $211000.0; the TTM figure through Jun 2026 stood at $44000.0 (up 12.82% YoY), while the FY2025 annual figure was -$110000.0, up 89.51% from the prior year.
- Change in Receivables came in at $211000.0 for Q2 2026 at Perspective Therapeutics, up from $52000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $618000.0 in Q3 2023 to a low of -$813000.0 in Q2 2024.
- Average Change in Receivables over 5 years is -$73277.8, with a median of -$42500.0 recorded in 2022.
- Year-over-year, Change in Receivables jumped 242.4% in 2023 and plunged 16700.0% in 2024.
- Over 5 years, Change in Receivables stood at -$245000.0 in 2022, then sank by 131.02% to -$566000.0 in 2023, then soared by 61.66% to -$217000.0 in 2024, then rose by 20.28% to -$173000.0 in 2025, then soared by 221.97% to $211000.0 in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $211000.0 in Q2 2026, $52000.0 in Q1 2026, and -$173000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - | 211,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 211,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | 147,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | -813,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | -566,000.00 |
| Sep 30, 2023 | 618,000.00 |
| Jun 30, 2023 | -251,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | -245,000.00 |
| Sep 30, 2022 | -434,000.00 |
| Jun 30, 2022 | -39,000.00 |
| Mar 31, 2022 | 493,000.00 |
| Dec 31, 2021 | 68,000.00 |
| Sep 30, 2021 | -111,000.00 |